![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 296, Issue 3, 890-897, March 2001
Isis Pharmaceuticals, Inc., Carlsbad, California
Plasma pharmacokinetics, biodistribution, excretion, and metabolism of
four modified 20-mer antisense oligonucleotides targeted to human
intercellular adhesion molecule-1 mRNA have been characterized in rats and compared with a first-generation phosphorothioate oligodeoxynucleotide (PS ODN), ISIS 2302. The modified oligonucleotides contained 2'-O-(2-methoxyethyl)
(2'-O-MOE) ribose sugar modifications on all or a
portion of the nucleotides in the antisense sequence. The
2'-O-MOE-modified oligonucleotides were resistant to
nuclease metabolism in both plasma and tissue. In general, plasma
pharmacokinetics was not substantially altered by addition of the
2'-O-MOE modification to PS ODN. Thus, plasma clearance
was dominated by distribution to tissues, broadly, with less than 10%
of the administered dose excreted in urine or feces over 24 h.
However, the 2'-O-MOE modification combined with the
phosphodiester (PO) backbone exhibited 10-fold more rapid plasma
clearance, with approximately 50% of the dose excreted in urine as
intact oligonucleotide. Consistent with its rapid and extensive
excretion, the PO 2'-O-MOE modification distributed to
very few organs in any substantial amount with the exception of the
kidney. Oligonucleotides that contained phosphorothioate backbones were
highly bound to plasma proteins. Indeed, the primary characteristic
that resulted in the most marked alterations in pharmacokinetics
appeared to be the affinity and capacity of these compounds to bind
plasma proteins. A balance of greater stability supplied by the
2'-O-MOE modification together with maintenance of
plasma protein binding appears to be necessary to ensure favorable pharmacokinetics of this new generation of antisense oligonucleotides.
This article has been cited by other articles:
|
|
 |
|
  S. Davis, S. Propp, S. M. Freier, L. E. Jones, M. J. Serra, G. Kinberger, B. Bhat, E. E. Swayze, C. F. Bennett, and C. Esau Potent inhibition of microRNA in vivo without degradation Nucleic Acids Res., November 16, 2008; (2008) gkn904v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Juliano, Md. R. Alam, V. Dixit, and H. Kang Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides Nucleic Acids Res., July 1, 2008; 36(12): 4158 - 4171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Graham, K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice J. Lipid Res., April 1, 2007; 48(4): 763 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Yu, T.-W. Kim, A. Hong, T. A. Watanabe, H. J. Gaus, and R. S. Geary Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 Drug Metab. Dispos., March 1, 2007; 35(3): 460 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Swayze, A. M. Siwkowski, E. V. Wancewicz, M. T. Migawa, T. K. Wyrzykiewicz, G. Hung, B. P. Monia, and a. C. F. Bennett Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals Nucleic Acids Res., January 28, 2007; 35(2): 687 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Tachas, S Lofthouse, C J Wraight, B F Baker, N B Sioufi, R A Jarres, A Berdeja, A M Rao, L M Kerr, E M d'Aniello, et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J. Endocrinol., April 1, 2006; 189(1): 147 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Davis, B. Lollo, S. Freier, and C. Esau Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res., January 1, 2006; 34(8): 2294 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J. Lipid Res., May 1, 2005; 46(5): 872 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Drygin, S. Barone, and C. F. Bennett Sequence-dependent cytotoxicity of second-generation oligonucleotides Nucleic Acids Res., December 16, 2004; 32(22): 6585 - 6594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Siwkowski, L. Malik, C. C. Esau, M. A. Maier, E. V. Wancewicz, K. Albertshofer, B. P. Monia, C. F. Bennett, and A. B. Eldrup Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing Nucleic Acids Res., May 17, 2004; 32(9): 2695 - 2706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Prakash, J. F. Johnston, M. J. Graham, T. P. Condon, and M. Manoharan 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo Nucleic Acids Res., February 3, 2004; 32(2): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Vickers, S. Koo, C. F. Bennett, S. T. Crooke, N. M. Dean, and B. F. Baker Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. A COMPARATIVE ANALYSIS J. Biol. Chem., February 21, 2003; 278(9): 7108 - 7118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Myers, S. Murthy, A. Flanigan, D. R. Witchell, M. Butler, S. Murray, A. Siwkowski, D. Goodfellow, K. Madsen, and B. Baker Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-alpha in Two Murine Models of Colitis J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Sewell, R. S. Geary, B. F. Baker, J. M. Glover, T. G. K. Mant, R. Z. Yu, J. A. Tami, and F. A. Dorr Phase I Trial of ISIS 104838, a 2'-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-alpha J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1334 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Arora, M. L. Cate, C. Ghosh, and P. L. Iversen Phosphorodiamidate Morpholino Antisense Oligomers Inhibit Expression of Human Cytochrome P450 3A4 and Alter Selected Drug Metabolism Drug Metab. Dispos., July 1, 2002; 30(7): 757 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Geary, O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, and A. A. Levin Absolute Bioavailability of 2'-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides following Intraduodenal Instillation in Rats J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 898 - 904. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
